Faster recovery after 25G than 20G vitrectomy

Article

But comparable functional and anatomical results in diabetic retinopathy patients

Twenty-five gauge (25G) microincision vitrectomy surgery (MIVS) can produce the same functional prognosis as conventional 20gauge (20G) vitrectomy in patients with proliferative diabetic retinopathy (PDR), but as the procedure is less traumatic for the eye, it reduces postoperative inflammation, induced astigmatism and patient discomfort, it is believed to result in faster recovery time compared with 20G vitrectomy. This means that MIVS has the potential to relieve the financial and temporal burdens of surgical treatment for PDR, representing great progress in the treatment of this complex vitreoretinal condition.

However, despite these advancements and despite the fact that 25G MIVS has now completely replaced 20G vitrectomy in some hospital settings, concrete data about the postoperative recovery period in the cases that underwent 25G MIVS had not previously been available. Therefore, Dr Tatsuhiko Sato (Osaka Rosai Hospital, Japan) and his team conducted a study1 to compare outcomes between the two procedures; specifically, they measured the duration of postoperative hospitalization (chosen as the index of postoperative recovery period) after 25G MIVS and compared it to that following 20G vitrectomy.

The team studied 159 eyes; the first group (n = 72) underwent 20G vitrectomy while the second group (n = 87) underwent 25G vitrectomy. There were no significant differences in patient demographics or preoperative ocular status between the two groups. All procedures were conducted by the same two experienced surgeons, working in a hospital that performs around 1000 vitreoretinal surgeries per year.

The researchers compared the surgical procedures and postoperative functional and anatomical outcomes between the two groups. Patients were permitted to be discharged from hospital when they displayed no signs of infection for five consecutive days after the vitrectomy, had no discomfort and no postoperative complications, such as retinal detachment and nonclearing vitreous haemorrhage. Eyes with vitreous cavities that were still filled with silicone oil at the last examination (baseline + ≥6 months) were classified as anatomical failures.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.